



PRESS RELEASE

Synucure Therapeutics Announces an Additional Strategic Financing of \$1.7 Million to Advance Its Neurodegenerative Disorders Program

MONTREAL, Octobre 29, 2026 – [Synucure Therapeutics](#) today announced the successful closing of an additional \$1.7 million financing through the issuance of preferred shares. The financing includes participation from new private investors and existing shareholders, including Fonds Impulsion, managed by Investissement Québec and funded by the Government of Québec.

Building on recent positive developments, this additional financing marks another important milestone in Synucure's growth and provides additional resources to support the company's next stage of development.

Synucure is advancing a proprietary cysteamine-based therapeutic program originating from the research of [Dr. Francesca Cicchetti](#), targeting Parkinson's disease and other neurodegenerative diseases. The company is also developing patented blood biomarkers designed to improve the diagnosis of Parkinson's disease.

“Our focus remains on building long-term value for our shareholders as we advance toward the next phase of Synucure's development. We are grateful for the support of seasoned private investors and Fonds Impulsion S.E.C., an institutional investor that is extremely valuable to us and supportive of our mission. Based on our current plan, we now have enough capital to bring us to our Series A, which will mark the debut of our clinical program.”

Sylvain Chrétien, CEO and cofounder of Synucure Therapeutics.

Among the new investors participating in this financing, Synucure is pleased to welcome Dr. Adrián Noriega de la Colina, a seasoned, internationally recognized scientist in the field of neurodegenerative disorders.

“I am very encouraged by their progress. The human brain remains the final frontier, and Parkinson's and Huntington's diseases represent some of its hardest challenges. Sylvain and

Francesca's scientific rigor and determination give me great confidence in Synucure's mission. I am certain this investment will help accelerate towards their clinical program and bring new hope to so many patients and their families.”

Dr. Adrián Noriega de la Colina, Physician-Scientist, Broad Institute of MIT and Harvard.

“Synucure’s progress confirms the potential of its approach and the importance of moving forward with its development. Through its renewed investment, Fonds Impulsion is supporting the company at a pivotal stage in its growth and helping it reach its next milestones.”

Alex Laverdière, Vice-President, Venture Capital, Investissement Québec.

About Synucure Therapeutics

[Synucure Therapeutics](#) is a Canadian biotechnology company dedicated to developing innovative therapies for neurodegenerative diseases. Founded in 2021, Synucure's primary mission is to advance the promising research led by [Dr. Francesca Cicchetti](#) on the therapeutic potential of cysteamine in Parkinson's disease and other brain degenerative disorders. Preclinical studies have demonstrated that cysteamine can prevent and/or reverse several pathological features associated with Parkinson's disease in multiple cellular and animal models.

In parallel, Synucure is developing patented blood biomarkers designed to provide an additional diagnostic tool for earlier and more accurate detection of Parkinson's disease through a simple blood test.

To learn more, visit www.synucure.com and follow us on [LinkedIn](#).

Information for the media:

Synucure Therapeutics

Dolorès Carballo

Phone: 514-893-7541

dcarballo@synucure.com

Investissement Québec

Samuel Bergeron

Advisor, Media and Government Affairs

Phone: 263 999-8144

samuel.bergeron@invest-quebec.com